Read more
Edited by two experts working at the pioneering pharmaceutical company and major global player in hormone-derived drugs, this handbook and reference systematically treats the drug development aspects of all human nuclear receptors, including recently characterized receptors such as PPAR, FXR and LXR. Authors from leading pharmaceutical companies around the world present examples and real-life data from their own work.
List of contents
Nuclear Receptors as Modern Drug Targets - a Historic PerspectiveTargeting the Nuclear Receptor - Cofactor InteractionUntangling the Estrogen Receptor WebSubtype Selective EstrogensEstrogen Receptors as Therapeutic Targets in Breast CancerProgesterone Receptor and ProgestinesProgesterone Receptor AntagonistsNonsteroidal Tissue Selective Androgen Receptor ModulatorsThe Glucocorticoid Receptor as Target for Classic and Novel Anti-inflammatory Therapy and Novel Glucocorticoid Receptor LigandsVitamin D Analogs as Modulators of Vitamin D Receptor ActionPPARs: Therapeutic Targets for Metabolic Disease and Type 2 DiabetesRetinoids in Clinical UseNuclear Receptors as Targets in Cardiovascular DiseasesNURR77 Family of Nuclear Receptors and its ModulatorsInduction of Drug Metabolism: The Role of Nuclear ReceptorsNuclear Receptor Targeted Screening Libraries and Chemogenomics Approaches
About the author
Hilmar Weinmann studied Chemistry at the universities of Tübingen and Hannover (Germany). He joined Schering in 1995, where he is currently a department head of Medicinal Chemistry. His main fields of expertise are in oncology, dermatology and gender healthcare.
Eckard Ottow is the head of medicinal chemistry at Schering AG in Berlin (Germany). He studied Chemistry at the University of Hannover (Germany) and received his PhD degree in 1982. He joined Schering AG in 1983, first in the field of endocrinology and later in oncology and CNS. In 2002, he was appointed to his present position as head of medicinal chemistry. He is also a honorary professor at the Technical University of Berlin.
Gerd Folkers is professor of pharmaceutical chemistry at the ETH Zürich since 1991. He studied pharmacy at the University of Bonn and earned his Ph.D. on structure-activity relationships of desapurines. He then moved to the University of Tübingen, where he completed his habilitation in pharmaceutical chemistry. During a stay with H.-D. Hoeltje in Bern, he studied new research methods in computer-aided molecular design and expanded this knowledge during other stays with T. Blundell at the Birkbeck College and E. Meyer at Texas A&M University.The focus of his research is the molecular interaction between drugs and their binding sites. Besides his work on the molecular mechanism of "conventional" nucleoside therapeutics against virus infections and cancer, his special interest has shifted to immuno-therapeutics.
Summary
Edited by two experts working at the pioneering pharmaceutical company and major global player in hormone-derived drugs, this handbook and reference systematically treats the drug development aspects of all human nuclear receptors, including recently characterized receptors such as PPAR, FXR and LXR. Authors from leading pharmaceutical companies around the world present examples and real-life data from their own work.
Report
"With increasing importance attributed to this area, the text is a welcome review of the current field.... The quality of the text is good with very readable chapters and many useful original literature references. The book will be clearly valuable for both academic and industrial groups engaged in drug discovery." ( Journal of Medicinal Chemistry , March 2009)
"This is an excellent book for scientists interested in adding or expanding expertise in nuclear receptor drug discovery to their skill set. The chapters are timely, well referenced into the 2008 literature, and focused on the chemistry of successful and emerging therapeutic small molecules." ( Journal of the American Chemical Society , March 10, 2009)
"The book is a good reference for medicinal chemists, pharmacologists and those working in the pharmaceutical industry." ( RoSearc h, December 2008)
